Search Results for: covid-19
Articles
ISR Signs Agreement With Gerresheimer for Clinical-Scale Production of IcoOne Nasal Inhalers May 31, 2022
The drug development company ISR has recently signed an agreement with Gerresheimer for large-scale production of the IcoOne nasal inhaler, for its Phase 3 study of its dry powder….
DFE Pharma Opens New Center of Excellence in India to Provide Fast-Track Formulation Services May 26, 2022
DFE Pharma recently announced the launch of its new Center of Excellence Closer to the Formulator (C2F) in Hyderabad, India. The C2F center is based in Genome Valley….
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201) May 25, 2022
Oncotelic Therapeutics, Inc. recently announced the clearance of the Phase 2 clinical trial protocol for mesothelioma after filing the protocol...GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 24, 2022
GeoVax Labs, Inc. recently announced the Chinese Patent Office has issued a Notice of Allowance for GeoVax’s patent application titled...Croda Announces the New Pharma Business May 18, 2022
Croda recently announced that its Health Care division will now become Croda Pharma, bringing its core speciality excipient portfolio together with the recent acquisition, Avanti Polar Lipids and its….
Pneumagen Announces Positive Top Line Results From Phase 1 Study Evaluating a Product Designed for the Prevention & Treatment of Viral Respiratory Tract Infections May 12, 2022
Pneumagen recently reported positive topline data from a Phase 1 study with Neumifil designed to evaluate safety and tolerability in...Update on Positive Pre-Clinical Results From AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease May 12, 2022
Aeterna Zentaris Inc. recently provided an update on the positive results from pre-clinical studies of Aeterna’s Autoimmunity Modifying Biologicals (AIM Biologicals), for the potential treatment of Parkinson’s Disease (PD)…..
SPECIAL FEATURE - PFS & Parenteral Drug Delivery: Self-Injection is Very Much the “New Normal” May 2, 2022
Contributor Cindy H. Dubin showcases how leading CDMOs and drug delivery developers are responding to current market trends to create ergonomic technologies that are patient friendly, easy to use, reduce needle anxiety, and feature improved packaging materials.
GLOBAL REPORT – 2021 Global Drug Delivery & Formulation Report: Part 2, Notable Drug Delivery and Formulation Product Approvals and Technologies of 2021 May 2, 2022
In part 2 of this 3-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on notable drug delivery and formulation product approvals.
EXECUTIVE INTERVIEW - PCI Pharma Services: Broadening Our Biologics Footprint, Together May 2, 2022
Shawn Cain, SVP Development & Manufacturing at PCI Pharma Services, discusses the recent acquisition, the opportunities this presents to Biopharma companies, and the current trends in the sterile fill-finish industry.
AUTOMATION SOLUTIONS - The Future of Lab Tech Will Combine Automation, Accuracy & Agility May 2, 2022
Rich Ellson and John Fuller, PhD, say accelerating development comes down to designing and using flexible automation solutions along with smarter instruments and new consumable paradigms to help meet researchers’ needs.
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease May 2, 2022
Vaxxinity, Inc. recently announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the US FDA for the treatment of Alzheimer’s disease…..
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease April 28, 2022
Vaxxinity, Inc. recently announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312...GeoVax Announces Issuance of Malaria Vaccine Patent April 26, 2022
GeoVax Labs, Inc. recently announced the US Patent and Trademark Office has issued Patent No. 11,311,612 to GeoVax, pursuant to...Genovac Acquires the Carterra LSA Instrument to Enable State-of-the-Art Antibody Screening & Characterization Services April 20, 2022
Genovac, a leading contract research and manufacturing organization (CRO/CMO) that discovers, develops, and manufactures antibodies for therapeutic, diagnostic, and research...TFF Pharmaceuticals Announces Safety & Pharmacokinetic Data From Phase 1 Study of Niclosamide Inhalation Powder April 19, 2022
TFF Pharmaceuticals, Inc. recently announced safety and pharmacokinetic (PK) data from its Phase 1 study of Niclosamide Inhalation Powder, which...Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults April 19, 2022
Aeterna Zentaris Inc. recently announced the European Patent Office (EPO) has issued a patent providing intellectual property protection of macimorelin...NEC & Shionogi Enter Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine April 18, 2022
NEC Corporation and Shionogi & Co., Ltd. recently announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic….
Ocugen to Commercialize COVAXIN in Mexico, Rights Now Encompassing All of North America April 18, 2022
Ocugen, Inc. and Bharat Biotech recently announced they have entered into an amendment to their Co-development, Supply and Commercialization Agreement to expand Ocugen’s exclusive….
CELL & GENE THERAPY - State of the Industry – Where is C> Headed? April 5, 2022
Bill Vincent believes if the industry wants to keep moving up the steep growth curve, then capacity and raw materials must be readily available. The innovations in therapies, platforms, and processes will all come with time, money, and increasing availability of resources.
